NEW YORK, Feb. 21, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on TSRO, TRVN, VNDA, and VSTM which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Tesaro Inc. (NASDAQ: TSRO), Trevena
On Tuesday, shares in Waltham, Massachusetts headquartered Tesaro Inc. recorded a trading volume of 1.06 million shares, which was above their three months average volume of 1.01 million shares. The stock ended at $62.30, rising 3.83% from the last trading session. The Company's shares are trading below their 50-day moving average by 13.24%. Furthermore, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have a Relative Strength Index (RSI) of 45.77.
On February 02nd, 2018, Tesaro announced that it will release its Q4 2017 financial results on February 27th, 2018, after the close of the US financial markets. That same day at 4:15 p.m. ET, the senior management team will host a conference call to discuss the Company's operating results as well as the status of its development programs and commercial products. A live audio webcast of the conference call will be available on the Company's website. Get the full research report on TSRO for free by clicking below at: www.wallstequities.com/registration/?symbol=TSRO
King of Prussia, Pennsylvania headquartered Trevena Inc.'s stock finished yesterday's session 2.67% lower at $1.64 with a total trading volume of 524,924 shares. The stock is trading below their 50-day moving average by 2.24%. Shares of the Company, which develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 48.93.
On February 02nd, 2018, Trevena announced the promotion of Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to Executive Vice President and COO, effective immediately. Ms. Bourdow brings to this newly created position over 25 years of experience at large and small commercial biopharmaceutical companies. The free technical report on TRVN can be accessed at: www.wallstequities.com/registration/?symbol=TRVN
At the close of trading on Tuesday, shares in Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc. climbed 1.17%, ending the day at $17.30. The stock recorded a trading volume of 555,713 shares, which was above its three months average volume of 510,570 shares. The Company's shares have advanced 19.31% in the last month, 30.57% in the previous three months, and 15.33% over the past year. The stock is trading 14.02% and 11.82% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 66.94.
On February 14th, 2018, Vanda Pharma announced results for Q4 and full year ended December 31st, 2017. For Q4 2017, total revenues were $44.3 million, total operating expenses were $46.4 million, and net loss was $(1.8) million. For the full year 2017, total revenues were $165.1 million, total operating expenses were $182.0 million, and net loss was $(15.6) million. Cash, cash equivalents, and marketable securities were $143.4 million as of December 31st, 2017. Sign up for free on Wall St. Equities and claim the latest report on VNDA at: www.wallstequities.com/registration/?symbol=VNDA
Needham, Massachusetts headquartered Verastem Inc.'s shares ended the day 0.91% lower at $3.28 with a total trading volume of 352,251 shares. The stock has gained 5.13% in the last month and 166.67% over the past year. The Company's shares are trading 0.53% below their 50-day moving average. Additionally, shares of Verastem, which focuses on discovering and developing drugs for the treatment of cancer, have an RSI of 49.67.
On February 07th, 2018, Verastem announced that the Company has submitted a New Drug Application to the US FDA seeking full approval for its lead product candidate duvelisib, a first-in-class oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and accelerated approval for the treatment of relapsed or refractory follicular lymphoma. See the free research coverage on VSTM at: www.wallstequities.com/registration/?symbol=VSTM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----tesaro-trevena-vanda-pharma-and-verastem-300601749.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All